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5 P450 monooxygenases catalyze the introduction of oxygen into a vast range of molecules and are known to have diverse functions in endogenous and exogenous metabolism (Ortiz de Montellano, 2005) . P450s in Families 1-3 are primarily involved in the metabolism of exogenous compounds; i.e., drugs and environmental pollutants, while Families 4-51 consist of enzymes primarily involved in the bioconversion of endogenous compounds; i.e., steroids, fatty acids, vitamins, and eicosanoids (Guengerich, 2005) . To date 57 human P450 (CYP or P450, P450 indicating the nucleotide or protein, while CYP indicating the gene in question) genes are known (http://drnelson.utmem.edu/CytochromeP450.html). The P450s can be divided into six major groups based on their main substrates: steroids, vitamins, fatty acids, eicosanoids, xenobiotics, and unknown (Nelson et al., 1996; Guengerich et al., 2005) . It is noteworthy, however, that a number of known P450s have assigned substrates in more than one of these groups and some substrates cannot be assumed to be true physiological substrates based only on their conversion rates (e.g. testosterone 6β-hydroxylation for hepatic P450 3A4), in the absence of other evidence of function. Although extensive research efforts have been directed towards elucidating the endogenous and exogenous functions of individual P450s, one-fourth of the human P450s still have not been assigned a catalytic activity and remain "orphans" Guengerich, 2008; Stark and Guengerich, 2007) (based on the terminology previously used for nuclear receptor proteins without known ligands (e.g. (Mangelsdorf and Evans, 1995) ). Our present working list of P450 orphans includes ~12 human P450s: 2A7, 2S1, 2U1, 2W1, 3A43, 4A22, 4F22, 4V2, 4X1, 4Z1, 20A1, and 27C1 Stark and Guengerich, 2007) .
Human P450 20A1 has, to our knowledge, only been mentioned in one publication (Marek et al., 2007) , in which a 230-bp mRNA transcript was reported in stellate cells prepared This article has not been copyedited and formatted. The final version may differ from this version. (http://www.ncbi.nlm.nih.gov/UniGene/). Orthologous nucleotide sequences have been found in a number of mammals, including rat (84% identity), mouse (85%), chimpanzee (99.6%), and chicken (72%) (http://drnelson.utmem.edu/CytochromeP450.html). None of these (putative) proteins has been studied to date.
In this work, P450 20A1 mRNA was found in human adult liver and brain, with a highly selective expression in brain tissues, i.e., substantia nigra, hippocampus, basal ganglia, and amygdala. mRNA expression analysis of the rat ortholog was also studied. Heterologous expression in Escherichia coli confirmed that this is a P450 enzyme. Some potential activities in the metabolism of steroids, model P450 substrates, and brain neurotransmitters by an N-terminaloptimized version of P450 20A1 were investigated. This article has not been copyedited and formatted. The final version may differ from this version. Fig. 1 ). The probe design was analyzed (compared to all known 57 human sequences) using the BLAST algorithm and found to selectively detect P450 20A1 (NM_177538.2). The blot was hybridized using a 32 P-labeled oligonucleotide probe for P450
20A1, according to the manufacturer's instructions (BD Biosciences-Clontech). The array was blocked using ExpressHyb solution containing salmon sperm DNA (1.5 mg, 20 min, 60ºC Bioscience, and β-actin primers were designed using freely available primer design programs.
The program was set at 95°C (3 min), followed by 40 cycles of 95°C (10 s)/55°C (45 s). A melting curve analysis was preformed after each run to establish that only one insert was formed. The iCyclerTM software calculates the threshold cycle at which fluorescence reaches a selected level. After amplification a melting curve was performed to ensure specific product formation.
The real-time PCR results were analyzed using the iCycler™ software, and the P450 20A1 expression levels were calculated using the comparative C t method and normalized to the levels of two housekeeping genes, GAPDH and 18S RNA. The expression of the housekeeping genes was analyzed as described above. To detect the human P450 20A1 sequence, forward (h20A1_F, , and the digestion fragments were visualized after separation using 1 and 2% agarose (w/v) gels. Sequencing of the products was performed in the Vanderbilt facility using the M13 (-20) forward (5-TGTAAAACGACGGCCACT) and reverse (5´-CAGGAAACAGCTATGAC) primers according to the manufacturer's instructions. All DNA sequences were analyzed using the OK BLAST similarity search tool (Altschul et al., 1997) .
A full-length transcript was ligated into the pCW monocistronic vector. Screening for full-length transcripts of rat P450 20A1 was performed using exon-specific primers, and putative full-length transcripts were submitted for sequencing (see Supplemental Data Figs In brief, a number of overlapping synthons were designed to span the cDNA sequence and used for primary PCA, followed by a one-step PCR reaction (94ºC, 5 min; 94º C, 30 s; 58 ºC, 30 s;72 ºC, 2 min (30 cycles); 72 ºC, 10 min). In order to decrease the error frequency the sequence was manually divided into two synthons (Synthon 1: 850 bp, Synthon 2: 601 bp) and later ligated together using an MscI site (Supplemental Data Table S1 , Fig. S7 ). An NdeI restriction site spanning the start codon was introduced at the 5'-end sequence, and the 3'-flanking sequence contained an XbaI restriction site. The resulting insert of the correct size was ligated into the pCW vector for both monocistronic and "bicistronic" vectors (the latter containing a human NADPH-P450 reductase cDNA downstream of the cDNA insert, between the NdeI and the XbaI sites) (Parikh et al., 1997 Fig. S6 ). Pfu Ultra High-Fidelity™ DNA polymerase (Stratagene, La Jolla, CA) was used for the PCR amplification at an annealing temperature of 58-60ºC. All PCR-products were purified using agarose gel electrophoresis and double digested using NdeI and XbaI before ligation into the vector. All modifications were confirmed by nucleotide sequence analysis in the Vanderbilt facility.
Heterologous Expression of P450 20A1. Expression of P450 20A1 constructs was performed in both E. coli DH5α cells and pGroEL/ES12 DH5α cells, the latter containing a chaperone system. Both the plasmids pGro12 ES/EL and each of the twelve constructs of pCW 20A1 were transformed into E. coli DH5α competent cells and selected on Luria-Bertani medium plates containing 50 µg ampicillin/ml or 50 µg ampicillin plus 20 µg kanamycin/ml, respectively.
Single colonies were grown overnight in Luria-Bertani liquid media (100 µg ampicillin/ml alone or with 50 µg kanamycin/ml) at 37ºC with 225 rpm gyrorotary shaking. Each overnight culture was then inoculated (1:100 dilution) into 50 ml of Terrific Broth containing 100 µg ampicillin/ml, 50 µg kanamycin/ml (when used), and a 0.025% (v/v) mixture of a trace element mixture (Sandhu et al., 1993) in a 250-ml flask. The cultures were incubated at 37ºC with gyrorotary shaking at 200 rpm until the OD 600 reached 0.5; P450 20A1 expression was induced with 1.0 mM D-isopropyl-β-galactoside and 0.5 mM 5-aminolevulinic acid. The addition of arabinose (1 mg/ml) was used to initiate pGroEL/ES12 transcription in the case of chaperones.
This article has not been copyedited and formatted. The final version may differ from this version. P450 concentrations were estimated with a CO-difference spectra assay (Omura and Sato, 1964 ) using an OLIS/Aminco DW2a spectrophotometer (On-Line Instrument Systems, Bogart, GA).
Assay of Cholesterol Oxidation. All bicistronic membrane samples (prepared using a vector also containing NADPH-P450 reductase) were tested using an NADPH oxidation assay (∆A 340, ∆ε 340 = 6.22 mM -1 cm -1 ) before use in the experiments with potential substrates. Assays of cholesterol oxidation were performed using a general procedure previously described (Wu et al., 2006a) . Bicistronic membranes containing human P450 20A1 (~100 pmol) or human P450 7A1
(100 pmol) (positive control, a generous gift of Dr. I. Pikuleva, University of Texas, Galveston, TX) (plus 200 pmol NADPH-P450 reductase and 30 µg L-α-dilauroyl-sn-glycero-3-phosphocholine in the case of purified P450 7A1) were incubated in 1.0 ml of 50 mM potassium phosphate buffer (pH 7.4) and 100 µM cholesterol together with 3 µl [4-14 C]-cholesterol (in C 2 H 5 OH, 2.66 × 10 5 dpm total). Reactions (at 37°C, 20 min) were initiated by the addition of an NADPH-generating system (Guengerich and Bartleson, 2006) . Reactions were quenched by the addition of 1.0 ml ethyl acetate, mixed using a vortex device, and analyzed essentially as previously described (Wu et al., 2006a 
UPLC-MS Analysis of Products of Incubations with Bicistronic P450 20A1
Membranes. Incubations with potential substrates were run for 30 min (0.1 nmol of P450 20A1
and NADPH-P450 reductase in membranes prepared from bacteria expressing bicistronic vectors) at 37°C, in a similar manner as described for cholesterol oxidation. All bicistronic membrane samples were tested using the NADPH oxidation assay (∆A 340, ∆ε 340 = 6.22 mM -1 cm -1 ) before use in the experiments with potential substrates. Extractions were performed using ethyl acetate, and the concentrated extracts were analyzed by LC-MS.
UPLC-MS/MS analysis was performed on a Waters Acquity UPLC system (Waters, Milford, MA) connected to a ThermoFinnigan LTQ mass spectrometer (ThermoFisher, Waltham, MA). Analysis was performed in the positive or negative ion electrospray ionization mode using an Acquity UPLC BEH octadecylsilane (C18) column (1.7 µm, 1.0 mm × 100 mm). Analyses were performed using a linear gradient from Buffer A (10 mM NH 4 CH 3 CO 2 in 5% CH 3 CN, v/v) to Buffer B (10 mM NH 4 CH 3 CO 2 plus 95% CH 3 CN, v/v). The temperature of the column was maintained at 55°C and the samples were injected with an autosampler system. Positive and negative ion electrospray conditions were as follow: source voltage 4 kV; source current 100 µA;
auxiliary gas flow rate setting 20; sweep gas flow rate setting 5; sheath gas flow setting 34; (Fig. 1) . However, the P450 20A1 heme binding region appears to miss one residue in the first part of the conserved FXXGXXXC sequence, reading FS_GTQEC. After the Cys residue, the third residue is a Glu, while most other P450s contain a conserved Gln residue.
This article has not been copyedited and formatted. The final version may differ from this version. expression was studied using both mRNA blotting and in situ fluorescence hybridization. A multiple tissue mRNA blot containing mRNA from >75 different tissues was hybridized using a P450 20A1 probe directed against residues 667-718, designed to differentiate P450 20A1 from all other human P450s using a multiple BLAST alignment program. The results indicated a strong specific expression mainly in human substantia nigra, and no expression was detectable in a number of other brain tissues using this approach (Fig. 3) . (Fig. 3) , specific primers designed to detect partial and putative full-length transcripts of P450 20A1 were used to perform independent conventional PCR of human substantia nigra, as well as whole human brain and a number of other brain regions (amygdala, hippocampus, basal ganglia, and cerebellum), along with fetal and adult liver. Bands of the expected size were detected in all tissues examined (data not presented). Real-time PCR was used to compare the levels of P450 20A1 mRNA expression in these tissues (Fig. 4) . The expression level in adult liver was at least 2-fold higher than in whole brain; however, the specific brain regions hippocampus and substantia nigra contained considerably higher mRNA levels. The results were normalized to a housekeeping gene; for graphic representation all of the other values are compared with adult liver (nominally set equal to 100) (Fig. 4) . However, it must be noted that these mRNA samples were from single donors and the issue of inter-individual variation has not been addressed (due to the difficulty of obtaining human brain regions from multiple donors, the investigation was also limited to expression levels within single individuals).
RT qPCR Analysis of Rat P450 20A1.
If P450 20A1 has a specific function in parts of human brain, one might expect to see similar localization patterns in rodents, in which the issue of interindividual variation of tissues is not a factor. Real-time PCR was used to compare the mRNA levels of P450 20A1 expression in these tissues. A number of considerations have to be made when using a reference gene to normalize expression results, because the reliablity of the housekeeping gene in question is important for the validity of the assay. Four common rat housekeeping genes-β-actin, GAPDH, cyclophilin A, and 18S ribosomal RNA-were investigated, GAPDH and cyclophilin A were chosen for further studies because they showed the highest and most invariant expression levels (low C t values).
A commercially available primer set directed against rat P450 20A1 indicated higher mRNA expression in both rat liver and heart than in brain (results not shown). Judging from the relative quantitation analysis, the P450 20A1 mRNA level was 3-to 4-fold lower in brain than in heart or liver, with reference to cyclophilin A and GAPDH. The corresponding values for exonspecific primer pairs, amplifying specifically exons 2 and 3 in order to ensure full-length P450
20A1 detection (vide infra), was C t 23.5 (brain) compared to C t 24.3 (heart) and C t 26.5 (liver).
The variability may be due to contributions from alternatively spliced transcripts (vide infra) in the case of the commercial primer set (Fig. 5) .
In situ hybridization of P450 20A1 in whole rat brain sections showed specific localization in the neurons of the substantia nigra, hippocampus, and amygdala (Fig. 6 ). This tissue distribution is similar to the tissue distribution pattern found in human brain by conventional and real-time PCR analysis (Figs. 4 and 6 ).
This article has not been copyedited and formatted. The final version may differ from this version. P450 20A1 mRNA was demonstrated to be constitutively expressed in rat brain, liver, and heart. mRNAs of both splice variants were detected in rat brain along with full-length mRNA, but liver and heart contained both full-length and transcripts missing exon 2s1 transcripts. This result implies that alternatively-spliced gene products of P450 enzymes may be generated in speciesand tissue-selective manners. Full-length transcripts have been detected in all three tissues using exon-specific primers for conventional RT-PCR. Heart and liver transcripts were successfully sequenced (Fig. 5, Supplemental Data Fig. S4 ).
This article has not been copyedited and formatted. The final version may differ from this version. Synthesis of Codon-optimized P450 20A1 cDNA. At the beginning of this project no P450 20A1 cDNA was available, either commercially or described in the literature. cDNA was prepared for heterologous expression using PCA of a large number of overlapping oligos. The sequence was codon-optimized in order to facilitate expression in an E. coli expression system, following protocols for other P450s that have been successfully expressed in this laboratory (Wu et al., 2006a; Wu et al., 2006b ). An alignment of the native-codon P450 20A1 sequence and two other mammalian P450 20A1 sequences is shown in Supplemental Data Fig. S6 . The P450 20A1
insert was later also ligated into a bicistronic vector containing both the P450 and human NADPH P450-reductase cDNAs (Parikh et al., 1997) .
Expression of N-Terminal Variants. Truncations and modifications of the N-terminus
of most mammalian P450s expressed in E. coli have been shown to increase the expression levels (Barnes et al., 1991; Richardson et al., 1995; Barnes, 1996; Guengerich et al., 1996) . The predictions of favorable truncations for a P450 are often based on alignments with close P450 family members; however in the case of human P450 20A1 this enzyme appears to be the sole member of P450 Family 20. With the assumption that the first part of the enzyme contains a membrane-binding structure that can be modified or removed, a number of different N-terminal modifications were introduced and expressed, based on previous work with P450s ( Fig. 2 and Supplemental Data Fig. S6 ). All of these expression trials yielded expression levels < 50 nmol/l crude culture; i.e., weak ferrous-CO difference spectra. P450 20A1 constructs 11 and 12 showed reproducible expression in the range of 150-250 nmol P450/l. Modification 11 is based on the Nterminal sequence MASRQAS… in front of the proline-rich region, and 12 is based on the MALLLAFV… sequence originally used with bovine P450 17A1 (Barnes et al., 1991; Barnes, This article has not been copyedited and formatted. The final version may differ from this version. 1996) in front of the third codon. The second codon (Ala) was changed to the E. coli-preferred variant GCT (Barnes et al., 1991) .
Expression trials were carried out using these constructs without and with co-expression of the molecular chaperones groES/EL12 in E. coli DH5α under different conditions of temperature and time (Fig. 7) . Membranes were prepared with a P450 recovery of 70% in the pellet fraction (10 5 × g, 1 h centrifugation, Gillam et al., 1993) . The peak centered near 450 nm was not seen with other constructs in which the P450 was not expressed. All subsequent enzyme reaction assays were carried out using bicistronic membranes prepared with construct 11.
Although cytochrome b 5 was not co-expressed in this system, previous work with P450s such as P450 3A4 have shown that the inclusion of cytochrome b 5 is not absolutely critical to enzymatic function in these systems (Parikh et al., 1997) . Bicistronic cultures of various modifications did not produce any blue color and the enzyme is not believed to be involved in 3-indole hydroxylation (Gillam et al., 1999; Gillam et al., 2000) .
Catalytic Assays. Several catalytic assays were attempted (using UPLC-MS systems) in order to investigate substrates known to be oxidized by other P450s and also compounds known to be important in the specific brain regions where P450 20A1 is localized. In order to verify that the NADPH-P450 reductase was capable of delivering electrons to this modified P450, the rate of NADPH reduction was measured, in the absence of substrate, and found to be 77 nmol NADPH oxidized/min/nmol P450 (at 23°C).
No oxidation was detected for the neurotransmitters dopamine, tyramine, serotonin, or melatonin. Further analysis with some known substrates of other P450s, e.g. arachidonic acid, docosahexaenic acid (Stark et al., 2005) , and a number of steroids known to be oxidized by androstenedione) were also investigated using methods adapted from studies with other P450s (Wang et al., 2000; Krauser and Guengerich, 2005) ), all yielding negative results. The limits of detection for these assays are listed in Supplemental Data Table S2 .
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
In this study we report initial characterization of one of the orphan P450s, P450 20A1.
This gene resides on human chromosome 2q33 and appears to be the only member of P450
Family 20 in both humans and rodents. Alignments between human and rodent sequences showed a high degree of sequence similarity (Supplemental Material Fig. S1 ). This conservation may suggest a possible physiological function. The codon-optimized P450 20A1 expressed in E.
coli was also prepared from this human sequence.
Initial mRNA dot blot analysis suggested a highly selective expression in human substantia nigra (Fig. 3) , meriting further characterization of the RNA distribution pattern of this enzyme. Further mRNA studies also established that P450 20A1 mRNA is expressed in several other brain regions including amygdala, hippocampus, basal ganglia, and cerebellum, along with human liver (Fig. 4) . P450s that are constitutively expressed in liver are in some cases found to be inducible in brain (Miksys et al., 2002) . P450 20A1 mRNA is expressed in both adult liver and brain. Although the overall total P450 20A1 mRNA expression level in human brain was ~2-fold lower than the corresponding value in human liver, certain brain regions (e.g. hippocampus, substantia nigra, and amygdala) exhibit high mRNA expression levels. In the case of hippocampus the increase is between 2-and 3-fold. Similar mRNA patterns were also detected in rat brain where P450 20A1 mRNA was detected in substantia nigra, hippocampus, and amygdala, as judged by in situ hybridization (Fig. 6 ).
The initial dot blot results showed expression only in the substantia nigra (Fig. 3) completely exclude the possibility. The difference in the patterns between the strong mRNA expression in substantia nigra detected on the dot blots (Fig. 3) and the real-time PCR analysis (Fig. 4) may be due to the presence of alternate spliced variants that do not translate into functional protein in substantia nigra, or simply to the more qualitative nature of the blot assay (Fig. 3) . Recently a brain specific variant of P450 1A1 (not present in liver from the same person)
was reported (Ravindranath et al., 2006) , but this result has not been independently confirmed.
Real-time PCR confirmed the extrahepatic expression pattern of P450 20A1 mRNA to be primarily centered in brain and showed a 2-to 3-fold increase in hippocampus and a >10-fold increase in the substantia nigra, as compared to adult liver. Because most available mRNAs are single donor mRNA samples, it is conceivable that the values may differ considerably between individuals and give rise to different expression patterns.
Although liver is the major organ involved in xenobiotic metabolism, a number of reports indicate that the P450 enzymes are present in extrahepatic tissues (e.g., lung, kidney, brain) and may contribute to the metabolism of xenobiotics in these organs (Miksys et al., 2002) . Some human P450s in brain have been found to oxidize substrates involved in neurological processes and metabolism of important endogenous mediators, e.g. cholesterol and neurotransmitters (Bogdanovic et al., 2001; Yu et al., 2003) . Many P450s found in brain also exhibit regional distribution (Strobel et al., 2001; Wu et al., 2005) . Other P450s show primary expression in brain.
P450 26B1 and the recently described P450 46B1 are involved in the metabolism of the endogenous substances all-trans retinoic acid and cholesterol, respectively (Bogdanovic et al., 2001; Trofimova-Griffin and Juchau, 2002; Mast et al., 2003) . Drugs used in treatment of exhibit specific function in certain brain regions (Kusumi et al., 1995; Riedl et al., 1998) .
At this point only limited information is available about the regulation and function of this new orphan P450. The tissue localizations of many of these P450s may provide clues as to their putative function, although their specific roles in endogenous metabolism may be difficult to predict based solely on their localization. An important question involving the brain P450s is whether they primarily are involved in the metabolism of endogenous substrates or in drug and xenobiotic metabolism (Miksys et al., 2002) . The development of better approaches to defining functions of the orphan proteins will be important for our understanding of these enzymes, and the exact function of this particular orphan remains to be elucidated.
This article has not been copyedited and formatted. The final version may differ from this version. coli (Wu et al., 2006b ) (see also Supplemental Material Figs. S1, S6). heart, A5, esophagus; A6, colon, transverse; A7, kidney; A8, lung; A9, liver; A10, leukemia, HL-60; A11, fetal brain; A12, yeast total mRNA; B1, cerebral cortex;; B2, cerebellum, right; B3, accumbens nucleus; B4, aorta; B5, stomach; B6, colon, descending; B7, skeletal muscle; B8, placenta; B9, pancreas; B10, HeLa S3; B11, fetal heart; B12, yeast tRNA; C1, frontal lobe (brain); C2, corpus callosum; C3, thalamus; C4, atrium, left; C5, duodenum; C6, rectum;, C7, spleen; C8, bladder; C9, adrenal gland; C10, leukaemia, K-562; C11, fetal kidney; C12, E. coli This article has not been copyedited and formatted. The final version may differ from this version. Burkitt's lymphoma, Daudi; F11, fetal thymus; F12, human C 0 t-1 DNA; G1, postcentral gyrus of cerebral cortex; G2, medulla oblongata; G3, -; G4, interventricular septum; G5, appendix; G6, -; G7, -; G8, ovary; G9, -; G10, colorectal adenocarcinoma, SW480; G11, fetal lung; G12, human DNA (100 ng); H1, pons; H2, putamen; H3, -; H4, apex of the heart; H5, colon, ascending; H6, -; H7 trachea; H8, -; H9, -; H10, lung carcinoma, A549; H11, -; H12, human DNA, 500 ng. The relative levels of P450 20A1 were determined using real-time PCR for adult liver, hippocampus, and substantia nigra, using GAPDH as a reference standard. Hybridization was carried out with a DIG-labeled alkaline phosphatase cDNA antisense probe.
Immunoreactivity was visualized by incubation of the sections by a BCIP/NBT Alkaline Phosphatase Substrate Kit™ (Vector Laboratories). Original magnification ×200. 
